Cyclo-oxygenase-1 and cyclo-oxygenase-2 and cardiovascular system

被引:3
|
作者
Lettino, M
Cantù, F
Mariani, M
机构
[1] IRCCS, Policlin S Matteo, CCU Cardiol, Dept Cardiol, I-27100 Pavia, Italy
[2] Univ Pisa, Inst Cardiol, Cardiothorac Dept, Pisa, Italy
关键词
aspirin; atherosclerosis; cyclo-oxygenase; endothelial cells; platelets; prostaglandin;
D O I
10.1016/S1590-8658(01)80154-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Prostaglandins play important roles in the pathophysiological mechanism of action of platelets and endothelial cells in the cardiovascular system. The two isoforms of cyclo-oxygenase, respectively cyclo-oxygenase-1 and cyclo-oxygenase-2, are differently expressed in these cells. Activated platelets show a relatively large amount of cyclo-oxygenase-1, whereas endothelial cells have the gene for cyclo-oxygenase-2, the expression of which follows cell activation. In the atherosclerosis lesion, prostaglandin synthesis is mainly mediated by the inducible cyclo-oxygenase-2 expressed in macrophages/foam cells, smooth muscle cells and endothelial cells. Aspirin, a selective platelet cyclo-oxygenase-1 inhibitor, still remains the most extensively studied antiplatelet agent, even though there is growing evidence that many other compounds could be valuable either in association, or alternatives in antithrombotic therapy.
引用
收藏
页码:S12 / S20
页数:9
相关论文
共 50 条
  • [31] Cyclo-oxygenase-2 and its inhibition in cancer - Is there a role?
    Liao, Zhonxing
    Mason, Kathryn A.
    Milas, Luka
    DRUGS, 2007, 67 (06) : 821 - 845
  • [32] Cyclo-oxygenase-2 in vascular smooth muscle (Review)
    Bishop-Bailey, D
    Hla, T
    Mitchell, JA
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 1999, 3 (01) : 41 - 48
  • [33] Expression of cyclo-oxygenase-2 in gastrointestinal carcinoid tumors
    Mizuno, Shigeaki
    Kato, Kimitoshi
    Hashimoto, Akemi
    Sugitani, Masahiko
    Sheikh, Aleemuzzaman
    Komuro, Sachiko
    Jike, Toyoharu
    Iwasaki, Ariyoshi
    Arakawa, Yasuyuki
    Nemoto, Norimichi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 (08) : 1313 - 1319
  • [34] Pharmacokinetics of rofecoxib - A specific cyclo-oxygenase-2 inhibitor
    Davies, NM
    Teng, XW
    Skjodt, NM
    CLINICAL PHARMACOKINETICS, 2003, 42 (06) : 545 - 556
  • [35] Cyclo-oxygenase-2 inhibitors and the kidney - A case for caution
    Noroian, G
    Clive, D
    DRUG SAFETY, 2002, 25 (03) : 165 - 172
  • [36] Cyclo-oxygenase-2 inhibitors and COPD: a bright spot?
    Effros, RM
    Casaburi, R
    THORAX, 2005, 60 (10) : 796 - 796
  • [37] Cyclo-Oxygenase-2 and its Inhibition in CancerIs There a Role?
    Zhongxing Liao
    Kathryn A. Mason
    Luka Milas
    Drugs, 2007, 67 : 821 - 845
  • [38] Cyclo-Oxygenase-2 Inhibitors and the KidneyA Case for Caution
    Gary Noroian
    David Clive
    Drug Safety, 2002, 25 : 165 - 172
  • [39] Cyclo-oxygenase-2 inhibitors to treat gastrointestinal bleeding
    Wardle, EN
    LANCET, 2001, 358 (9292): : 1550 - 1550
  • [40] Clinical pharmacology of lumiracoxib - A selective cyclo-oxygenase-2 inhibitor
    Rordorf, CM
    Choi, L
    Marshall, P
    Mangold, JB
    CLINICAL PHARMACOKINETICS, 2005, 44 (12) : 1247 - 1266